At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET
Vistagen announced constructive FDA feedback from a Type C meeting on fasedienol for social anxiety disorder, including endorsement of the LSAS as a primary endpoint and guidance on interim assessments. The company plans to submit a revised Phase 3 protocol focusing on the general SAD population. No approval, funding, or timeline was provided, and the company's $7M market cap raises significant financing risk.
- FDA provided constructive feedback on using LSAS as primary endpoint in a future Phase 3 study for fasedienol in SAD.
- FDA recommended interim assessments (eDiaries, patient surveys) to evaluate acute and longer-term effects.
- Vistagen plans to submit a revised protocol focusing on the general SAD population, not just acute treatment.
- FDA recognized fasedienol's reported safety profile and potential to benefit a broad SAD population.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access